The Caledonian-Record

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment ...

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis; ...
Healio

First patient enrolled LYNX-2 study of eye drop for reduced visual acuity in low light

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The LYNX-2 study is being conducted under conditions of ...
Seeking Alpha

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

MR-142 Achieved Primary Endpoint of ≥15-letter (≥3-line) Gain in Mesopic Low Contrast Distance Visual Acuity in Comparison to Placebo Results Showed Patient-Reported Functional Benefit in Treating ...
Healio

Analysis identifies predictors of poorer acute optic neuritis outcomes

Please provide your email address to receive an email when new articles are posted on . Being male or aged older than 40 years were consistently associated with poorer acute optic neuritis outcomes.